In-practice Evaluation of Atacand 16mg Antihypertensive Effect
Overview
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: January 2009
Arms, Groups and Cohorts
- 1
- Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
Clinical Trial Outcome Measures
Primary Measures
- Decrease in blood pressure
- Time Frame: once after 4 weeks
Participating in This Clinical Trial
Inclusion Criteria
- Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided – Signed and dated Patient Informed Consent (ICF) Exclusion Criteria:
- Hypersensitivity to the active substance or to any of the excipients of Atacand.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- AstraZeneca
- Provider of Information About this Clinical Study
- Janis Dobelis, AstraZeneca MC Latvia
- Overall Official(s)
- Agrita Hartmane, Study Director, AstraZeneca
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.